Disturbed Lipids, Lipoproteins and Triglyceride-Rich Lipoproteins as Well as Fasting and Nonfasting Non-High–Density Lipoprotein Cholesterol in Post-Renal Transplant Patients

REFERENCES

• Marubayashi S, Ohdan H, Tashiro H, Tokita D, Onoe T, Hayamizu K, Asahara T, Doi S, et al. Studies on post-renal dyslipidemia in kidney transplant patients. Hiroshima J Med Sci. 2005; 54: 39–45
   PubMedGoogle Scholar
• Maki KC, Galant R, Davidson MH. Non-high-density lipoprotein cholesterol: The forgotten therapeutic target. Am J Cardiol. 2005; 96(Suppl.)59K–64K
   Google Scholar
• Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Junger I, Waddilius G. Apolipoproteins versus lipids as indicators of coronary risk and as targets for statin therapy. Lancet 2003; 361: 777–780
   PubMed Web of Science ®Google Scholar
• Fellström B, Holdaas H, Jardine AG, Holme I, Nyberg G, et al. Effect of fluvastatin on renal and points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int. 2004; 66: 1549–1555
   PubMed Web of Science ®Google Scholar
• Fellström B. Nonimmune risk factors for chronic renal allograft disfunction. Transplantation 2001; 71: SS10–SS16
   Google Scholar
• Paul LC. Chronic allograft nephropathy: An update. Kidney Int. 1999; 56: 783–793
   PubMed Web of Science ®Google Scholar
• Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomized, placebo-controlled trial. Lancet 2003; 361: 2024–2031
   PubMed Web of Science ®Google Scholar
• Desmeules S, Arcand-Bosse J-F, Bergeron J, Douville P, Agharazii M. Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis. 2005; 45: 1067–1072
   Google Scholar
• Kimak E, Solski J, Baranowicz-Gąszczyk I, Książek A. A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients. Ren Fail. 2006; 28: 483–486
   PubMed Web of Science ®Google Scholar
• Kimak E, Książek A, Solski J. Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure. Clin Chem Lab Med. 2006; 44: 64–69
   PubMed Web of Science ®Google Scholar
• Badiou S, Garrigue V, Dupuy AM, Chong G, Cristol JP, Mourad G. Small dense low-density lipoprotein in renal transplant recipients: A potential target for prevention of cardiovascular complications?. Transplant Proc. 2006; 38: 2314–2316
   PubMed Web of Science ®Google Scholar
• Sattar N, Williams K, Sniderman AD, Agostino RD, Haffner SM. Comparison of the association of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the insulin resistance atherosclerosis study. Circulation 2004; 110: 2687–2693
   PubMed Web of Science ®Google Scholar
• Lee S-J, Moye LA, Campos H, Williams GH, Sacks FM. Hypertriglyceridemia but not diabetes status is associated with coronary heart disease. Atherosclerosis 2003; 167: 293–302
   PubMedGoogle Scholar
• Chan DC, Watts GF, Ng TWK, Uchida Y, Sakai N, Yamashita S, Barrett PHR. Apolipoprotein B-100 kinetics and static plasma indices of triglyceride-rich lipoprotein metabolism in overweight men. Clin Biochem. 2005; 38: 806–812
   Google Scholar
• Fellström B. Risk factors for and management of post-transplantation cardiovascular disease. BioDrugs. 2001; 15: 261–278
   PubMed Web of Science ®Google Scholar
• Lemieux I, Houde I, Pascot A, Lachance J-G, Noël R, Radeau T, Despres J-P, Bergeron J. Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int. 2002; 62: 1839–1847
   PubMed Web of Science ®Google Scholar
• Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 1990; 68: 379–384
   Google Scholar
• Hilbrands LB, Demacker PN, Hoitsma AJ, et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol. 1995; 5: 2073–2081
   PubMed Web of Science ®Google Scholar
• Donahoo WT, Kosmiski LA, Eckel RH. Drugs causing dyslipoproteinemia. Endocrinol. Metab. Clin. North. Am. 1998; 27: 677–697
   PubMedGoogle Scholar
• Walczak DA, Calvert D, Jarzembowski TM, Testa G, Sankary HN, Thielke J, et al. Increased risk of post-transplant diabetes mellitus despite early steroid discontinuation in Hispanic kidney transplant recipients. Clin Transplant. 2005; 19: 527–531
   Google Scholar
• Abramowicz D, del Carmen Rial M, Vitko S, del Castillo D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol. 2005; 16: 2234–2240
   PubMed Web of Science ®Google Scholar
• Woodside KJ, Nichols SD, Hunter GC, Gugliuzza KK, Daller JA. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. Transpl Proc. 2005; 37: 1877–1879
   PubMedGoogle Scholar
• Włodarczyk Z, Walaszewski J, Perner F, Vitko S, Ostrowski M, Bachleda P, Kokot F, et al. Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regiments. Transplant Int. 2005; 18: 157–162
   PubMed Web of Science ®Google Scholar
• Kwong M, Wasan KM. Cholesteryl ester transfer protein facilitates the movement of water-insoluble drugs between lipoproteins: a novel biological function for a well-characterized lipid transfer protein. Biochem Parmacol. 2002; 64: 1669–1675
   PubMed Web of Science ®Google Scholar